Business
Chairman’s Open Letter to Shareholders
ImmuPharma PLC has successfully completed a fundraising, with shareholders approving resolutions for a £6 million Lanstead subscription and a £468,000 WRAP retail offering, significantly strengthening the company's balance sheet and extending its cash runway to at least H2 2028. This capital will advance strategic priorities, including securing a value-enhancing partnering agreement for its P140 auto-immune technology platform in 2026 and accelerating the development program for Kapiglucagon for type 1 diabetes. The Lanstead subscription includes a Sharing Arrangement with an 8p Benchmark Price, potentially allowing the company to benefit from future share price performance. Disclaimer*
About this update from Immupharma Plc
RNS REACH | 9 April 2026 ImmuPharma PLC ("ImmuPharma" or the "Company") Chairman's Open Letter to Shareholders ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, outlines below an open letter to shareholders from the Chairman, Tim McCarthy. This follows on from this week's announcement, confirming that both resolutions proposed at the General meeting held on Tuesday 7 April 2026, were approved by Shareholders. Dear Shareholders I wanted to take this opportunity, on behalf of the ImmuPharma Board, to thank you for your strong support at this week's General Meeting, where both resolutions relating to the proposed Lanstead placing and WRAP retail offering were approved. Resolution 1 received 91.46% support and Resolution 2 received 88.91%, reflecting clear shareholder endorsement of the Company's corporate strategy, as outlined in our announcement of 17 March 2026, (https://www.immupharma.co.uk/updates/). The approval of these resolutions enables us to complete the fundraising, comprising a £6 million Lanstead subscription, alongside a £468k WRAP retail component. This significantly strengthens our balance sheet and provides the capital required to advance our key strategic priorities. Our primary focus remains on securing a value-enhancing partnering agreement for our lead auto-immune technology platform, P140, during 2026. Recent progress continues to reinforce both the scientific rationale and commercial positioning of this program, and the management team is actively engaged in progressing discussions toward this objective. The P140 update, issued on 27 March 2026, further strengthened the program's foundations, highlighting the first Combined Search and Examination Report for the UK patent application, supported by new study data. In addition, a scientific manuscript is now in preparation for submission to a peer-reviewed journal. Together, these developments enhance the credibility and long-term commercial potential of P140. Following the General Meeting, we are now investing in our second key asset, Kapiglucagon, for type 1 diabetes. We have kickstarted an accelerated development program with a clear two-year plan, which was outlined in the recent Investor Meet Company presentation (https://www.immupharma.co.uk/updates/interviews/).The funding se...